In 2015, a phase II study investigated the efficacy of pembrolizumab, a humanized IgG4 antibody directed against surface-expressed PD-1, in three separate cohorts of 41 patients with MSI-H and MSS CRC tumors, and MSI-H tumors from other sites (non-CRC). This evidence concerns the gene PDCD1 and colorectal carcinoma.